NSG BioLabs operates fully equipped, certified BSL-2 laboratory and office infrastructure offering equipment, efficient operations, capital efficiency, and access to expert teams and global networks. Its primary product is co-working lab and office space across 35,000 sq ft in Biopolis, Singapore, supporting R&D for health, biomedical, agrifood, and industrial biotechnology companies. The company provides services and benefits to resident teams working in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, and synthetic biology. Since 2019 it has supported over 40 resident companies, whose startups have collectively raised nearly US$400M and achieved notable business milestones. NSG BioLabs is led by CEO and Founder Daphne Teo and markets itself as a capital-efficient operational platform for early-stage life sciences innovators. The company plans to use new financing to expand its facilities, augment infrastructure, and enhance value‑add services and networking opportunities for residents.

Total raised

$15M

Funding rounds

1

Latest round

Equity

Latest activity

May 2024